| Title |
Inhibitors of the PD-1/PD-L1 axis for the treatment of head and neck cancer: current status and future perspectives
|
|---|---|
| Published in |
Drug Design, Development and Therapy, July 2017
|
| DOI | 10.2147/dddt.s140687 |
| Pubmed ID | |
| Authors |
Xiongwen Ran, Kai Yang |
| Abstract |
Head and neck cancer (HNC) is a common malignant tumor, but traditional therapeutic methods have unsatisfactory curative effects and many complications occur. Hence, there is an urgent need to develop therapeutic methods that can elicit curative effects as well as low toxic and few side effects. With the development of cancer molecular biology and immunology, targeted therapy for immune checkpoints of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) has shown enormous development prospects for HNC treatment. Groundbreaking progress has been achieved in the treatment of recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). This review describes current treatment by PD-1- and PD-L1-targeted drugs for HNC. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 65 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 65 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 10 | 15% |
| Student > Master | 9 | 14% |
| Other | 6 | 9% |
| Student > Ph. D. Student | 6 | 9% |
| Student > Doctoral Student | 4 | 6% |
| Other | 14 | 22% |
| Unknown | 16 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 20 | 31% |
| Biochemistry, Genetics and Molecular Biology | 9 | 14% |
| Agricultural and Biological Sciences | 3 | 5% |
| Nursing and Health Professions | 2 | 3% |
| Immunology and Microbiology | 2 | 3% |
| Other | 10 | 15% |
| Unknown | 19 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 July 2017.
All research outputs
#22,764,772
of 25,382,440 outputs
Outputs from Drug Design, Development and Therapy
#1,753
of 2,268 outputs
Outputs of similar age
#286,158
of 326,871 outputs
Outputs of similar age from Drug Design, Development and Therapy
#41
of 47 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,268 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 326,871 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 47 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.